FindTrial
Sign In

TQB2102

DRUG2 trials

Sponsors

Fudan University, Henan Cancer Hospital

Conditions

Breast CancerBreast NeoplasmBreast TumorsEarly-stage Breast CancerHER2 + Breast CancerHER2-negative Breast CancerHER2-positive Breast CancerHormone Receptor Negative Tumor

Phase 2

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
RecruitingNCT05582499
Fudan UniversityBreast Cancer, Breast Neoplasm, Breast Tumors +7
Start: 2022-11-01End: 2028-09-30Target: 716Updated: 2025-08-22
Efficacy of TQB2102 Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer.
Not yet recruitingNCT07136974
Henan Cancer HospitalBreast Cancer, HER2 + Breast Cancer
Start: 2025-09-01End: 2030-08-30Target: 280Updated: 2025-08-22

Related Papers

Abstract GS1-04: HER2-Directed Antibody-Drug Conjugate SHR-A1811 in the Neoadjuvant Treatment of HER2-positive Early Breast Cancer: a Prospective, Randomized, Open-label, Phase 2 Trial
Clinical Cancer Research2025-06-13
Abstract P2-11-06: Neoadjuvant chemotherapy plus camrelizumab vs. chemotherapy in patients with locally advanced immunomodulatory triple-negative breast cancer: a prospective, randomized, open-label, phase 2 trial
Clinical Cancer Research2025-06-13
Rational and trial design of FASCINATE-N: a prospective, randomized, precision-based umbrella trial
Therapeutic Advances in Medical Oncology2024-01-017 citations